PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis
| Autor: | A. J. C. Van Den Brule, E.C.M. Zeestraten, Inès J. Goossens-Beumer, Tom van Wezel, Harm J. T. Rutten, Cornelis J.H. van de Velde, Arantza Farina Sarasqueta, Valery E.P.P. Lemmens, Gesina van Lijnschoten, Ronald van Eijk, Peter J. K. Kuppen, Hans Morreau, Jan Willem T. Dekker |
|---|---|
| Přispěvatelé: | Pathology |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Poor prognosis Class I Phosphatidylinositol 3-Kinases Colon carcinoma medicine.disease_cause Phosphatidylinositol 3-Kinases Young Adult Exon Internal medicine medicine Humans Young adult neoplasms Aged Aged 80 and over Mutation Prognostic factor business.industry General Medicine Middle Aged Prognosis Tumor formation Stage III Colon Cancer Protein kinase domain Colonic Neoplasms Molecular Medicine Female PIK3CA mutations business Biomarkers |
| Zdroj: | Cellular Oncology, 34(6), 523-531 Cellular oncology, 34(6), 523-531. IOS Press |
| ISSN: | 2211-3428 |
| Popis: | Background PIK3CA mutations in the helical domain (in exon 9) and in the kinase domain (exon 20) cause tumor formation by different means. We aimed to determine the effects of each of these mutations on survival of colon carcinoma patients. Methods A large cohort of 685 colon carcinoma patients was tested for PIK3CA mutations in exons 9 and 20 by single nucleotide primer extension (N=428) or by real time PCR (N=257). Results PIK3CA mutation rate was 13%. 66 of 83 (79.5%) were in exon 9 and 17 of 83 (20.5%) in exon 20. In survival analysis, PIK3CA mutations in exon 9 and 20 had different effects on patient outcome. The PIK3CA exon 20 mutation conferred a poorer disease free survival compared to patients with wild type alleles and exon 9 mutations (Log rank p=0.04 and p=0.03 respectively) and cancer specific survival (Log rank p=0.03 and p=0.056 respectively) in stage III patients. In stage I and II this negative effect on outcome was not seen. Conclusions PIK3CA mutation in exon 20 is a negative prognostic factor in stage III colon cancer patients. Moreover, this negative effect is not present in stage I and II patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink